期刊文献+

冻干水痘减毒活疫苗的接种反应及免疫原性观察 被引量:8

Adverse Reaction and Immunogenicity Induced by Freeze-dried Live Attenu-ated Varicella Vaccine
原文传递
导出
摘要 目的观察国产冻干水痘减毒活疫苗的接种反应及免疫原性。方法选择460名观察对象,于接种后30min、6h、24 h、48 h、72 h、4~10 d进行随访,观察一般反应和异常反应,通过电话和自动报告收集30 d内的异常反应。采用膜免疫荧光抗体法(FAMA)检测观察对象免疫前后的抗水痘-带状疱疹病毒(VZV)抗体水平,并计算抗体阳性率、抗体几何平均滴度(GMT)及增长倍数。结果460名观察对象接种疫苗后,在观察期未观察到严重的局部反应和全身反应,也未观察到异常反应,抗体总阳性率为98.31%,免疫后抗体GMT水平平均为147.38,比免疫前提高38.18倍。6~12岁组免疫后抗体GMT水平高于1~5岁组,且差异有统计学意义。结论国产冻干水痘减毒活疫苗具有良好的安全性和免疫原性。 Objective To observe the adverse reaction and immunogenicity induced by freeze-dried live attenuated varicella vaccine. Methods A total of 460 subjects were immunized with domestic freeze-dried live attenuated varicella vaccine, and general adverse reactions and abnorulal reactions were followed-up 30 rain, 6 h, 24 h, 48 h, 72 h and 4 - 10 d after immunization. The abnormal reactions within 30 d were collected through telephone and the report by subjects themselves. The antibody titers against varicell-zoster virus(VZV) of the subjects before and after immunization were determined by FAMA, and the antibody positive rate as well as antibody GMT and its increasing fold were calculated. Results No severe local or systemic adverse reactions or abnormal reactions were observed in 460 subjects during the whole clinical trial. The total positive of antibody was 98. 31%. The GMT of antibody after immunization was 147. 38, which increased by 38. 18 folds compared with that before immunization. The GMT of antibody in subjects aged 6 - 12 years were significantly higher than those aged 1 - 5 years. Conclusion Domestic freeze-dried live attenuated varicella vaccine showed good safety and immunogenicity.
出处 《中国生物制品学杂志》 CAS CSCD 2009年第7期702-704,共3页 Chinese Journal of Biologicals
关键词 冻十水痘减毒活疫苗 接种反应 免疫原性 Freeze-dried live attenuated varicella vaccine Adverse reaction Immunogenicity
  • 相关文献

参考文献8

  • 1WHO. Requrements for varicella vaccine (live). WHO TRS, 1994, 848: 22-37.
  • 2Vazquez M, LaRussa PS, Gershon AA, et al. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med, 2001, 344 ( 13): 955-960.
  • 3Takahashi M, Otsuka T, Okuno Y, et al. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet, 1974, 2 (7892): 1288-1290.
  • 4http://www.fda.gov / cber / approvltr / varmer031795L.htm.
  • 5金连梅,冯子健.2005-2006年全国水痘疫情分析[J].疾病监测,2007,22(4):251-252. 被引量:107
  • 6王树巧,李长贵,李燕婷,袁家麟,陶红,王志军,吕国贞,王宪明,陈志慧,谢广中.国产冻干水痘减毒活疫苗的安全性和免疫原性研究[J].中国计划免疫,2000,6(6):334-347. 被引量:28
  • 7王连成,刘晔,李莉,李占春,李彦成,哈秀杰,徐秀凤,阎素志,王文忠,南一范,周铁群,王剑峰,邱平,李长贵.国产冻干水痘减毒活疫苗免疫效果观察[J].华南预防医学,2003,29(2):30-31. 被引量:10
  • 8Chaves SS, Haber P, Walton K, et al. Safety of varicella vaceine after licensure in the United States: experience from reports to the Vaccine Adverse Event Reporting System, 1995-2005. J Infect Dis, 2008, 197 (Suppl 2): S170-S177.

二级参考文献12

  • 1程朝霞,向辉,李标.人群水痘—带状疱疹病毒流行率及发病状况分析[J].中国公共卫生管理,2004,20(4):358-359. 被引量:38
  • 2徐冰,王树巧,谢广中.水痘疫苗及其免疫策略[J].中国计划免疫,2005,11(3):238-242. 被引量:55
  • 3Tan AY, Connett CJ, Connett GJ, et al. Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals /Oka) in healthy children. Eur J Pediatr, 1996, 155: 706.
  • 4Asano Y. Varicella vaccine: the Japanese experience. J Infect Dis, 1996, 176: 310.
  • 5Nagi AL, Staehle BO, Kuter BJ, et al. Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatr Infect Dis J, 1996, 15:49.
  • 6《全国突发公共卫生事件相关信息报告管理工作规范》[S].卫生部.2005.
  • 7卢振花 王宝珠.北京市-幼儿园水痘流行的调查.中国计划免疫,2000,6(3):150-150.
  • 8Takahashi M. Prevention of virus - related neurological diseases by vaccines[J]. Vaccine, 1997,15 (1):61-64.
  • 9曹惠霖,杜军,贾志远,詹美云,王稳,刘丹,丁丽新,董振英,王伟,梁建华,袁国娟,李燕婷,铁映臻,李志秀.我国部分地区人群中水痘-带状疱疹病毒流行率[J].中国计划免疫,1998,4(1):38-40. 被引量:33
  • 10周铁群,王剑锋,邱平,李长贵,韩秀娟,殷文武,李志仁,万卓越,金艾顺,张静,黄丽娟,王开利.儿童水痘血清流行率调查及其疫苗免疫效果[J].中华流行病学杂志,1998,19(5):271-273. 被引量:32

共引文献140

同被引文献103

引证文献8

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部